Загрузка...
CMET-21. TOLERANCE AND OUTCOMES OF STEREOTACTIC RADIOSURGERY COMBINED WITH ANTI-PD1 (PEMBROLIZUMAB) FOR MELANOMA BRAIN METASTASES
Anti-PD1 antibodies are currently the first-line treatment for patients with metastatic BRAF wild- type melanoma, alone or combined with the anti-CTLA4 mAb, ipilimumab. To date, data on safety and the outcomes of patients treated with the anti-PD1 mAbs, pembrolizumab (PB) or nivolumab, combined with...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692939/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.169 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|